Novo Nordisk unveiled new real-world evidence at ESC 2025 suggesting that Wegovy (semaglutide 2.4 mg) is associated with a substantially lower risk of major adverse cardiovascular events than tirzepatide in adults with overweight or obesity and established cardiovascular disease without diabetes. In matched U.S. cohorts of 10,625 patients each, continuous users of Wegovy experienced a 57% greater relative reduction in the composite of heart attack, stroke, or death from any cause versus tirzepatide over a mean follow-up of 3.8–4.3 months. In an all-treated analysis that included patients with therapy gaps, Wegovy was associated with a 29% relative reduction over roughly eight months of follow-up. Event counts were low but directionally consistent, with 15 events in the Wegovy group versus 39 with tirzepatide among continuous users.
The strategic signal is clear: competition in obesity is shifting from pounds lost to lives saved. Novo Nordisk is stitching together a narrative that combines SELECT’s randomized 20% MACE reduction versus placebo with two real-world datasets (SCORE and now STEER) to argue for molecule-level cardiovascular differentiation. That reframes the GLP-1 market as a cardiometabolic outcomes market, where comparative effectiveness—however provisional—can sway prescribers, payers, and care pathways long before head-to-head randomized trials read out.
Why this matters now is straightforward. For patients with obesity and established CVD, cardiologists and primary care physicians are increasingly the point of initiation, not just obesity specialists. Transparent, outcomes-focused positioning could steer these prescribers toward semaglutide, particularly in health systems prioritizing cardiovascular risk reduction targets. For payers and PBMs, the presence of a U.S. outcomes indication for Wegovy and mounting RWE may justify formulary preference, tighter step therapy, or outcomes-based arrangements in defined cardiovascular populations. For Lilly, the pressure intensifies to deliver positive cardiovascular outcomes trials for tirzepatide in both diabetes and obesity settings to neutralize this narrative; until then, commercial leverage tilts toward Novo in high-risk cohorts.
Still, the STEER findings need careful interpretation. This is a retrospective, propensity-matched analysis with a short follow-up and small absolute event numbers, which are susceptible to channeling bias, differences in titration and persistence, and residual confounding. The significant relative effects over brief intervals raise questions about durability and the extent to which adherence and patient selection drive the signal. Regulators will continue to prioritize randomized evidence. Medical Affairs teams should anticipate HCP scrutiny regarding methodology, data transparency, and subgroup consistency, and be prepared with pragmatic guidance on persistence, dose optimization, and comorbidity management.
The broader trend is unmistakable: real-world comparative evidence is becoming a frontline commercial tool, not just a post-marketing obligation. Cardiometabolic brands are moving to win on outcomes that matter to hospital systems and risk-bearing payers—MACE reduction, heart failure symptoms, and functional status—rather than weight alone. That creates a new bar for the next wave of incretin and poly-agonist entrants, where label-ready outcomes and robust RWE will be table stakes for access and differentiation.
The following six to twelve months will test whether payers operationalize cardiovascular differentiation into contract terms and pathway design, and whether supply and pricing frictions blunt that advantage. The pivotal question for the market is whether molecule-specific cardiovascular benefits become the decisive formulary lever before head-to-head randomized data arrive—and which company converts that evidence into preferred access and multidisciplinary adoption the fastest.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
